BMRN vs TEM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BMRN shows bullish fundamentals based on deterministic rules. Financial strength is strong (F-Score 8/9). Key strengths include strong valuation and growth metrics. Price trades at a 361.1% premium to fair value estimate ($12.25), limiting near-term upside from a valuation perspective.
Tempus AI exhibits critical financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across profitability and operational efficiency. While the company demonstrates explosive revenue growth of 83% YoY, this is offset by deep negative margins and a high Debt/Equity ratio of 2.70. The bearish outlook is further reinforced by aggressive insider selling, including significant divestments by the CEO and CFO, and a technical trend score of 0/100. Despite analyst optimism, the fundamental health metrics suggest a high-risk profile.
Compare Another Pair
Related Comparisons
BMRN vs TEM: Head-to-Head Comparison
This page compares BioMarin Pharmaceutical Inc. (BMRN) and Tempus AI, Inc. (TEM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.